Saniona (SANIOS) Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SANIOS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 12.94 |
| 52 Week High | SEK 26.65 |
| 52 Week Low | SEK 11.56 |
| Beta | 1.22 |
| 1 Month Change | 1.49% |
| 3 Month Change | -7.11% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -54.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANIOS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 0.2% |
| 1Y | n/a | -2.0% | 19.1% |
Return vs Industry: Insufficient data to determine how SANIOS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how SANIOS performed against the UK Market.
Price Volatility
| SANIOS volatility | |
|---|---|
| SANIOS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SANIOS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine SANIOS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 43 | Thomas Feldthus | saniona.com |
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor; SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; SAN2668, a therapy for severe pediatric epilepsies, including developmental epileptic encephalopathies; and SAN2465, a negative allosteric modulator to treat major depressive disorder.
Saniona AB (publ) Fundamentals Summary
| SANIOS fundamental statistics | |
|---|---|
| Market cap | SEK 1.85b |
| Earnings (TTM) | SEK 219.56m |
| Revenue (TTM) | SEK 429.29m |
Is SANIOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANIOS income statement (TTM) | |
|---|---|
| Revenue | SEK 429.29m |
| Cost of Revenue | SEK 5.75m |
| Gross Profit | SEK 423.54m |
| Other Expenses | SEK 203.98m |
| Earnings | SEK 219.56m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 27, 2026
| Earnings per share (EPS) | 1.59 |
| Gross Margin | 98.66% |
| Net Profit Margin | 51.14% |
| Debt/Equity Ratio | 0% |
How did SANIOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 10:18 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Saniona AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Novod | Nordea Markets |
| Jesper Ilsoe | Nordea Markets |
| Fredrik Thor | Redeye |